Abstract
Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility and low bone mass. Low bone density and fracture is a cause of morbidity. Limited data exists on bisphosphonate treatment in patients under 24 months of age. The objective of the study was to examine the safety and efficacy of pamidronate in children under 24 months with OI. To do so, we carried out a retrospective chart review and analysis of OI patients started on intravenous pamidronate under 24 months of age. Pamidronate was administered in three-day cycles. Growth, the number of fractures, and lumbar bone mineral densities were recorded both prior to and after treatment initiation. A total of 18 patients were reviewed. Five were classified as OI type I, seven were type III, and six were type IV. The mean age at treatment initiation was 12 months (range 11 days to 23 months). The mean lumbar z score at baseline was −3.63, which improved to −1.53 at one year (P < 0.01) and 0.79 (P < 0.01) at the end of the study. The fracture rate improved from 68 fractures in 209 months (0.32 fractures/patient-month) before treatment to 41 fractures in 1,248 months (0.03 fractures/patient-month) post-treatment (P < 0.05). Height standard deviation score (SDS) was conserved from baseline to end of study (−2.12 ± 2.45 vs. −2.45 ± 2.73) (P = 0.05) with an average follow-up of 73 months. The only adverse effect recorded in six infants was fever during the initial pamidronate infusion. Treatment with intravenous pamidronate is safe, significantly improves lumbar bone mineral density (L-BMD), and reduces fracture rates in young infants with OI while preserving linear growth.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Glorieux FH (2007) Treatment of osteogenesis imperfecta: who, why, what? Horm Res 68:8–11
Glorieux FH (2008) Osteogenesis imperfecta. Best Pract Res Clin Rheumatol 22:85–100
Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101–116
DiMeglio LA, Ford L, McClintock C, Peacock M (2004) Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35:1038–1045
Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846–1850
Hasegawa K, Inoue M, Seino Y, Morishima T, Tanaka H (2009) Growth of infants with osteogenesis imperfecta treated with bisphosphonate. Pediatrics international: Off J Japan Pediatric Soc 51:54–58
Burr DB (2002) Targeted and nontargeted remodeling. Bone 30:2–4
Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK (1996) Long-term effects of clodronate on growing rat bone. Bone 18:191–196
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534
Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD (2004) Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24:195–197
Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM (1979) Physical growth: national Center for Health Statistics percentiles. Am J Clin Nutr 32:607–629
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952
Astrom E, Soderhall S (2002) Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356–364
Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Investig 110:1293–1299
Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF (2013) Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr 79:333–340
Rauch F, Cornibert S, Cheung M, Glorieux FH (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827
(2006) WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 450:76–85
Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, Bundak R, Saka N (2008) Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop 28:483–487
Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111:1030–1036
Kalajzic I, Terzic J, Rumboldt Z, Mack K, Naprta A, Ledgard F, Gronowicz G, Clark SH, Rowe DW (2002) Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse. Endocrinology 143:1594–1601
Munns CF, Rauch F, Mier RJ, Glorieux FH (2004) Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35:231–234
Conflict of interest
All authors have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kusumi, K., Ayoob, R., Bowden, S.A. et al. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. J Bone Miner Metab 33, 560–568 (2015). https://doi.org/10.1007/s00774-014-0618-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-014-0618-2